RAD June 2021 Virtual Conference Abstracts & Posters

Abstracts have been published in the September 2021 issue of the British Journal of Dermatology and can be found here: https://onlinelibrary.wiley.com/doi/10.1111/bjd.20648.

#465 - Incidence of bacterial and non-bacterial conjunctivitis in patients with atopic dermatitis treated with dupilumab: a US multi-database cohort study

Maria C. Schneeweiss, MD, Richard Wyss, PhD, Kristyn Chin, BS, Joseph F. Merola, MD, MMSc, Jonathan I. Silverberg, MD, PhD, MPH, Arash Mostaghimi, MD, MPH, MPA, Sebastian Schneeweiss, MD, ScD


#466 - Long-term efficacy of baricitinib 2-mg for the treatment of atopic dermatitis in North America

Eric L. Simpson, Mark Boguniewicz, Lindsey Finklea, Edward Lain, Luna Sun, Sherry Chen, Robinette Angle, Tracy Cardillo, Fabio P. Nunes, Jonathan I. Silverberg


#467 - Pediatric Patients With Atopic Dermatitis (AD) Have a High Burden of Atopic Comorbidities: Results From a Large Worldwide Survey

Jonathan. I. Silverberg, Eric L. Simpson, Stephan Weidinger, Sebastien Barbarot, Lysel Brignoli, Tarek Mnif, Grece Saba, Noah A. Levit, Gaëlle Bégo-Le Bagousse, Dimittri Delevry, Ana B. Rossi


#468 - Long-Term Efficacy and Safety Data for Dupilumab in a Phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in Patients Aged ≥ 6 to 12 Years With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD)

Michael J. Cork, Diamant Thaçi, Lawrence Eichenfield, Peter D. Arkwright, Zhen Chen, John T. O’Malley, Ashish Bansal


#469 - Efficacy and Safety of Dupilumab for up to 1 Year in a Phase 3 Open-Label Extension (OLE) Trial (LIBERTY AD PED-OLE) in Adolescents With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD)

Andrew Blauvelt, Emma Guttman-Yassky, Eric L. Simpson, John Browning, Zhen Chen, Ashish Bansal, John T. O’Malley


#470 - Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis: a pooled analysis of data from 7 randomized, placebo-controlled studies

Norma P.M. Rubini, Jonathan I. Silverberg, Mario C. Pires, Zhen Chen, Jingdong Chao, Gaëlle Bégo-Le Bagousse


#471 - Early Trends of Disease Improvement in Adult Patients With Atopic Dermatitis Treated With Dupilumab: Real-World Data From the PROSE Registry

Jerry Bagel, Gil Yosipovitch, David M. Pariser, Haixin Zhang, Daniel Richman, Andrew Korotzer,


#472 - Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis

Peter Anderson, Jenny Austin, Jennifer H. Lofland, James Piercy, Vijay N. Joish


#473 - Rapid Itch Improvement with Upadacitinib with or without Concomitant Topical Corticosteroids (TCS) in Moderate-to-Severe Atopic Dermatitis (AD): Results from 3 Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)

Andrew Blauvelt, MD, MBA; Michael R Ardern-Jones, MBBS, DPhil; Thomas Bieber, MD, PhD; Chih-ho Hong, MD; Chia-Yu Chu, MD, PhD; Meng Liu, PhD6; Yang, PhD; Barry Ladizinski, MD, MPH, MBA; Henrique D Teixeira, PhD; Brian M Calimlim, DrPH, MS; Jacob P Thyssen, MD, PhD, DmSci


#475 - Discontinuation of Topical Corticosteroids in Upadacitinib-Treated Patients with Moderate-to-Severe Atopic Dermatitis: Analysis from the AD Up Phase 3 Trial

Kristian Reich, Mark Boguniewicz, Kenji Kabashima, Sebastien Barbarot, Giampiero Girolomoni, Pedro Mendes-Bastos, Amy Gamelli, Yingyi Liu, Henrique Teixeira, and April Armstrong


Page 2 of 7
Results 11 - 20 of 65
© 2021 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.